Wedbush Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

Wedbush Securities’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$278K	Buy	12,705 +3,651	+40%	+$75.9K	0.01%	1008
2026 Q1	$212K	Buy	+9,054	New	+$197K	0.01%	1099
2025 Q1	–	Sell	-10,000	Closed	-$132K	–	1181
2024 Q4	$132K	Hold	10,000	–	–	﹤0.01%	1069
2024 Q3	$193K	Hold	10,000	–	–	0.01%	1006
2024 Q2	$205K	Hold	10,000	–	–	0.01%	1070
2024 Q1	$238K	Hold	10,000	–	–	0.01%	997
2023 Q4	$216K	Hold	10,000	–	–	0.01%	926
2023 Q3	$145K	Hold	10,000	–	–	0.01%	964
2023 Q2	$209K	Hold	10,000	–	–	0.01%	916
2023 Q1	$211K	Hold	10,000	–	–	0.01%	917
2022 Q4	$255K	Hold	10,000	–	–	0.01%	800
2022 Q3	$240K	Hold	10,000	–	–	0.01%	815
2022 Q2	$192K	Hold	10,000	–	–	0.01%	937
2022 Q1	$174K	Hold	10,000	–	–	0.01%	1008
2021 Q4	$219K	Hold	10,000	–	–	0.01%	1025
2021 Q3	$191K	Hold	10,000	–	–	0.01%	1076
2021 Q2	$172K	Hold	10,000	–	–	0.01%	1082
2021 Q1	$224K	Buy	+10,000	New	+$226K	0.01%	938

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Wedbush Securities's SNDX Position: Q2 2026 in Review

Wedbush Securities increased its Syndax Pharmaceuticals (SNDX) stake by 40% in Q2 2026, buying an estimated $75.9K and bringing the position to 12,705 shares worth $278K. The position accounts for 0.01% of the portfolio, ranked #1008.

Wedbush Securities first reported a position in SNDX in Q1 2021 and has held it in 18 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Wedbush Securities held 12,705 shares of Syndax Pharmaceuticals worth $278K as of Q2 2026.
Wedbush Securities bought 3,651 Syndax Pharmaceuticals shares in Q2 2026, an estimated $75.9K.
Syndax Pharmaceuticals made up 0.01% of Wedbush Securities's portfolio in Q2 2026, its #1008 holding.
Wedbush Securities first reported a position in Syndax Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.